Analyzing Sarepta Therapeutics (NASDAQ:SRPT) & ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Profitability

This table compares ANI Pharmaceuticals and Sarepta Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	6.87%	17.15%	8.29%
Sarepta Therapeutics	1.20%	2.20%	0.58%

Risk and Volatility

ANI Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Institutional & Insider Ownership

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for ANI Pharmaceuticals and Sarepta Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	0	4	0	3.00
Sarepta Therapeutics	0	3	14	0	2.82

ANI Pharmaceuticals currently has a consensus target price of $81.00, suggesting a potential upside of 38.39%. Sarepta Therapeutics has a consensus target price of $177.65, suggesting a potential upside of 10.53%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe ANI Pharmaceuticals is more favorable than Sarepta Therapeutics.

Earnings and Valuation

This table compares ANI Pharmaceuticals and Sarepta Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$486.82 million	2.52	$18.78 million	$1.60	36.58
Sarepta Therapeutics	$1.24 billion	12.22	-$535.98 million	$0.11	1,461.09

ANI Pharmaceuticals has higher earnings, but lower revenue than Sarepta Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

ANI Pharmaceuticals beats Sarepta Therapeutics on 8 of the 14 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.